Ownership history in CM Management, LLC Β· 21 quarters on record
This page tracks every 13F SEC filing in which CM Management, LLC reported a position in COHERUS BIOSCIENCES INC (CHRS). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π CM Management, LLC underperformed the S&P 500 by β44.1% annually on this CHRS position. Timing score: 33% (6/18 decisions correct). Average cost basis: $3.06. Maximum drawdown during holding period: β95.8%.
β Significantly underperformed the S&P 500 by 44.1% ann.
11 quarters analyzed
β οΈ Poor timing β buys often preceded drops, trims preceded rallies.
6 of 18 add/trim decisions correct
Best entry: $0.73 (2025 Q2) Β· Worst: $17.38 (2020 Q4)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
16 adds Β· 2 trims. Bought during 13 of 16 down-price quarters. π Consistently bullish β fund kept accumulating this position.
π CM Management, LLC has been actively increasing its CHRS allocation β a bullish signal from insiders.
Currently 2.51% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size